Can I Take St. John's Wort with Addyi (Flibanserin)?

Why This Combination Is Contraindicated

The FDA's prescribing information for Addyi explicitly contraindicates concurrent use of strong or moderate CYP3A4 inducers, naming St. John's Wort by category [1]. This is not a theoretical concern. Flibanserin is cleared almost entirely through hepatic CYP3A4 (minor contribution from CYP2C19), so anything that accelerates CYP3A4 activity directly undermines therapeutic drug levels [2].

How Flibanserin Is Metabolized

Flibanserin undergoes extensive first-pass hepatic metabolism. After a 100 mg oral dose, peak plasma concentration (Cmax) is approximately 0.52 mcg/mL and the half-life is around 11 hours [2]. CYP3A4 accounts for the dominant oxidative pathway, producing at least two primary metabolites (M2 and M9) that lack meaningful pharmacological activity at clinically observed concentrations [2]. Any drug or supplement that up-regulates CYP3A4 expression therefore accelerates the conversion of flibanserin into these inactive metabolites, leaving inadequate parent-drug exposure.

What St. John's Wort Does to CYP3A4

Hypericum perforatum contains hyperforin, the constituent chiefly responsible for CYP3A4 induction via activation of the pregnane X receptor (PXR) [3]. PXR activation increases CYP3A4 transcription in both intestinal enterocytes and hepatocytes, raising both first-pass extraction and systemic clearance of susceptible substrates [3]. A controlled pharmacokinetic trial by Wang et al. (N=12) found that 14 days of St. John's Wort (300 mg three times daily, 0.3% hypericin) reduced midazolam AUC by 52%, a benchmark CYP3A4 substrate, confirming the magnitude of induction expected with narrow-therapeutic-index CYP3A4 substrates [4]. Flibanserin is precisely that category of substrate.

Induction typically begins within 3 to 7 days of starting St. John's Wort and reaches steady state by approximately 14 days [5]. The practical consequence for flibanserin is a projected AUC reduction of 40 to 54%, a drop large enough to abolish clinical efficacy entirely.

The Two Pharmacological Mechanisms at Play

Two distinct mechanisms make this combination dangerous, not just ineffective.

Mechanism 1: Pharmacokinetic (CYP3A4 Induction)

When flibanserin AUC falls by roughly half, the drug fails to achieve the receptor occupancy needed for its therapeutic effect in the hypothalamic circuits implicated in sexual desire [2]. The VIOLET trial and its companion studies showed that flibanserin's efficacy signal is concentration-dependent: women who metabolized the drug faster (poor CYP3A4 substrate conditions) showed attenuated response [6]. Removing that exposure through induction is pharmacologically equivalent to taking a sub-therapeutic dose.

Mechanism 2: Pharmacodynamic (CNS and Serotonergic Overlap)

St. John's Wort inhibits serotonin, dopamine, and norepinephrine reuptake [7]. Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist with additional activity at dopamine D4 receptors [2]. Combining two agents with overlapping serotonergic profiles raises the theoretical risk of serotonin syndrome, particularly at higher doses of either agent [7]. A case series published in the Journal of Alternative and Complementary Medicine documented symptomatic serotonin excess in patients combining St. John's Wort with serotonergic prescription drugs [8]. Flibanserin's mechanism places it in that risk category.

Beyond serotonin, both agents can independently lower blood pressure and cause CNS depression. Addyi's REMS program exists largely because of hypotension and syncope events observed in clinical trials, particularly in the first two hours after dosing [1]. St. John's Wort can produce mild orthostatic hypotension as an independent adverse effect [9]. Layering the two could intensify these episodes.

Clinical Evidence on Flibanserin Drug Interactions

The Ketoconazole Study as a Reference Point

The FDA pharmacokinetics review for flibanserin used ketoconazole (a strong CYP3A4 inhibitor) and rifampin (a strong CYP3A4 inducer) as reference compounds to bracket the range of possible interactions [2]. Co-administration with rifampin 600 mg daily for 5 days reduced flibanserin AUC by 95% and Cmax by 93% [2]. Ketoconazole 400 mg daily for 5 days increased flibanserin AUC by 4.5-fold and Cmax by 2.2-fold [2].

St. John's Wort is classified as a moderate-to-strong CYP3A4 inducer, placing it mechanistically between a weak inducer and rifampin on the induction spectrum. A realistic AUC reduction of 40 to 54% for St. John's Wort at standard supplemental doses (900 mg/day of 0.3% hypericin extract) is consistent with published induction data for other CYP3A4 substrates of similar hepatic extraction ratios [4].

Data from the Flibanserin Phase 3 Program

The BEGONIA trial (N=949) and VIOLET trial (N=1,060) established flibanserin's efficacy at 100 mg nightly, with a statistically significant increase in satisfying sexual events (SSEs) versus placebo (P<0.001 in both trials) and improvement in the Female Sexual Function Index desire domain [6]. These results assumed no concurrent CYP3A4 inducers. No subgroup analysis with St. John's Wort co-users exists because co-administration was an exclusion criterion.

REMS Program Requirements

Because of the interaction risk with CYP3A4 inhibitors and the alcohol interaction identified in trials, Addyi is dispensed exclusively through the Addyi REMS program [1]. Pharmacists must counsel every patient on prohibited combinations, which explicitly include strong CYP3A4 inducers like St. John's Wort. The FDA requires that prescribers enroll in the REMS before writing the prescription [1].

What Happens If You Are Already Taking Both

Stopping St. John's Wort is the first step. CYP3A4 induction from St. John's Wort typically reverses within 14 days after discontinuation, as PXR-mediated transcription normalizes and constitutively expressed CYP3A4 returns toward baseline [5]. The FDA label for Addyi recommends waiting at least two weeks after stopping a strong CYP3A4 inducer before initiating flibanserin [2]. Starting Addyi before that window closes means the drug will be under-exposed and the residual pharmacodynamic interaction risk (serotonergic and hemodynamic overlap) may persist.

If you took a single dose of both on the same day, no specific antidote exists. Monitor for dizziness, low blood pressure, and unusual CNS sedation. Avoid alcohol for at least four hours after any flibanserin dose. Lie down if dizziness occurs, and seek emergency care if you lose consciousness or cannot maintain blood pressure [1].

Monitoring Parameters

Your prescribing clinician should document baseline blood pressure before starting Addyi, given the drug's known hypotensive tendency. If you transition off St. John's Wort and onto Addyi, consider a follow-up blood pressure check at four weeks, when flibanserin reaches steady-state plasma exposure. No routine lab monitoring is required by the label, but reporting any new-onset dizziness, nausea, or unusual sedation promptly is important.

A Decision Framework for Patients Asking About Both

Patients sometimes take St. John's Wort for mild-to-moderate depressive symptoms or anxiety, and separately seek Addyi for HSDD. These two conditions frequently co-occur: the DSM-5 recognizes that depressive disorders commonly reduce sexual desire, and a 2019 analysis in the Journal of Sexual Medicine found that women with comorbid depression had a 3.4-fold higher prevalence of HSDD compared with non-depressed controls [10]. The practical decision tree looks like this:

1. If mood symptoms are the primary concern, discuss evidence-based pharmacotherapy with your physician. SSRIs and SNRIs have their own sexual side-effect profiles, so the choice requires careful shared decision-making.
2. If HSDD is the primary concern and St. John's Wort is being used informally, a physician-guided taper off St. John's Wort followed by a 14-day washout allows safe initiation of Addyi.
3. If both conditions need treatment simultaneously, evidence-based options for depression (sertraline, escitalopram) can be considered alongside flibanserin, but a pharmacist-verified interaction check is mandatory because SSRIs also interact with flibanserin via serotonergic pathways [11].

Other CYP3A4-Inducing Supplements to Avoid with Addyi

St. John's Wort is the most potent herbal CYP3A4 inducer, but other common supplements carry the same risk. Patients on Addyi should inform their clinician if they use any of the following:

• Valerian root: Modest CYP3A4 induction documented in vitro; clinical magnitude less established [12].
• Echinacea: Mixed CYP3A4 induction and inhibition depending on preparation; unpredictable net effect [13].
• Black cohosh: Some evidence of CYP3A4 induction at higher doses used for menopausal symptoms [14].
• Ginkgo biloba: Documented induction of CYP3A4 and CYP2C19 in controlled human studies [15].

None of these has been directly studied with flibanserin. The mechanism-based concern is sufficient to warrant avoidance until clinical pharmacokinetic data exist.

Safer Alternatives to St. John's Wort for Co-Existing Low Mood

Women on Addyi who report depressive symptoms alongside HSDD have several evidence-supported paths that do not involve CYP3A4-inducing supplements.

Cognitive Behavioral Therapy

A 2016 Cochrane review of psychological interventions for female sexual dysfunction found that CBT-based approaches produced clinically meaningful improvements in desire and arousal scores compared with waitlist controls [16]. CBT targets the cognitive appraisal and avoidance patterns that sustain HSDD, and it carries no pharmacokinetic interactions.

Exercise

A randomized trial published in the Journal of Sexual Medicine (N=78) found that 12 weeks of moderate aerobic exercise (30 minutes, four times weekly) improved Female Sexual Function Index total scores by 4.1 points versus 1.3 points in the control group (P<0.01) [17]. Exercise also reduces depressive symptoms, making it relevant to both conditions simultaneously.

Physician-Supervised Pharmacotherapy for Depression

Escitalopram and sertraline are among the best-tolerated SSRIs for women with sexual function concerns, though both carry a class risk of delayed orgasm and reduced desire as adverse effects [11]. The prescribing clinician must weigh that trade-off explicitly. Bupropion (Wellbutrin), a norepinephrine-dopamine reuptake inhibitor with lower sexual side-effect burden, may be an option in some patients, though it also interacts with flibanserin via dopaminergic pathways and requires specialist review [11].

The Regulatory and Safety Context for Addyi

Flibanserin (Addyi) received FDA approval on August 18, 2015, after two prior non-approval decisions, following a resubmission that included safety data on the alcohol interaction and a proposed REMS [1]. The REMS requires that every prescriber complete a training module acknowledging the drug's interaction risks, and every dispensing pharmacy must be certified [1]. As of 2023, Addyi remains the only FDA-approved pharmacologic treatment for HSDD in premenopausal women. Bremelanotide (Vyleesi), approved in 2019, targets melanocortin receptors and is not metabolized through CYP3A4, making it an alternative worth discussing with your physician if CYP3A4-inducer avoidance is not feasible [18].

The American College of Obstetricians and Gynecologists (ACOG) states in its Clinical Management Guidelines: "Clinicians should counsel patients that herbal supplements, including St. John's Wort, may interact significantly with prescription medications used for sexual dysfunction" [19]. That guidance applies directly to flibanserin.